Neutralizing antibodies, new laboratory tests against SARS-CoV-2

Descripción del Articulo

Introduction: in this review we will know the details of this new laboratory test, used to quantify neutralizing antibodies against SARS-CoV-2. This diagnostic test begins to have a greater role, due to the process of infection and vaccination in the world, to understand the mysteries of the correla...

Descripción completa

Detalles Bibliográficos
Autor: Figueroa Montes, Luis Edgardo
Formato: artículo
Fecha de Publicación:2022
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:amp.cmp.org.pe:article/2191
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/2191
Nivel de acceso:acceso abierto
Materia:Afinidad de Anticuerpos
Pruebas Serológicas
Infecciones por Coronavirus
Inmunogenicidad Vacunal
COVID-19
Antibody Affinity
Serologic Tests
Coronavirus Infections
Immunogenicity Vaccine
id REVCMP_8375203f2285061b3bdfa69e98e5a24b
oai_identifier_str oai:amp.cmp.org.pe:article/2191
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Neutralizing antibodies, new laboratory tests against SARS-CoV-2Anticuerpos neutralizantes, nuevas pruebas de laboratorio contra el SARS-CoV-2Figueroa Montes, Luis EdgardoFigueroa Montes, Luis EdgardoAfinidad de AnticuerposPruebas SerológicasInfecciones por CoronavirusInmunogenicidad VacunalCOVID-19Antibody AffinitySerologic TestsCoronavirus InfectionsImmunogenicity VaccineCOVID-19Introduction: in this review we will know the details of this new laboratory test, used to quantify neutralizing antibodies against SARS-CoV-2. This diagnostic test begins to have a greater role, due to the process of infection and vaccination in the world, to understand the mysteries of the correlate of immune protection. Content: neutralizing antibodies have the ability to block the ability of the virus to bind to the ACE2 receptor in human cells and these antibodies allow to eliminate the effect of invading microorganisms. Their activity is generated by proteins on the surface of viruses, which they bind to "block" infection. Neutralizing antibodies are defined in vitro by their ability to block the entry, fusion or exit of the coronavirus, that is, they are functional antibodies. Summary: Currently there are different laboratory tests (high-throughput immunoassay tests), which have the ability to detect immunoglobulin G anti-protein S antibodies to SARS-CoV-2 and which correlate with the gold standard laboratory tests for the determination of these antibodies. It is crucial that these high-throughput immunoassay tests are manufacturing validated against gold standard methods to determine the presence of neutralizing antibodies. Perspective: this review aims to expand the knowledge of this new test, which in the future will allow defining the immunological correlate values ​​generated by vaccines or by a previous infection.Introducción: en la presente revisión conoceremos los detalles de esta nueva prueba de laboratorio, utilizada para cuantificar los anticuerpos neutralizantes contra el SARS-CoV-2. Esta prueba diagnóstica comienza a tener un mayor protagonismo, a razón del proceso de infección y vacunación en el mundo, para comprender los misterios del correlato de protección inmunológica. Contenido: los anticuerpos neutralizantes tienen la capacidad de bloquear la capacidad del virus, para unirse al receptor ACE2 en las células humanas y estos anticuerpos permiten eliminar el efecto de microorganismos invasores. Su actividad se genera por las proteínas situadas en la superficie de los virus, a las que se unen para «bloquear» la infección. Los anticuerpos neutralizantes se definen in vitro por su capacidad para bloquear la entrada, fusión o salida del coronavirus, es decir son anticuerpos funcionales. Resumen: en la actualidad existen diferentes pruebas de laboratorio (pruebas de inmunoensayo de alto rendimiento), que tienen la capacidad de detectar anticuerpos inmunoglobulinas G anti proteína S del SARS-CoV-2 y que se correlacionan con las pruebas de laboratorio gold standard para la determinación de estos anticuerpos. Es crucial que estas pruebas de inmunoensayo de alto rendimiento, sean validadas en su fabricación contra métodos gold standard para determinar la presencia de anticuerpos neutralizantes. Perspectiva: esta revisión pretende ampliar el conocimiento de esta nueva prueba, que en un futuro permitirán definir los valores de correlato inmunológico generados por las vacunas o por una infección previa.Colegio Médico del Perú2022-02-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/219110.35663/amp.2021.384.2191ACTA MEDICA PERUANA; Vol. 38 No. 4 (2021): October - DecemberACTA MEDICA PERUANA; Vol. 38 Núm. 4 (2021): Octubre - Diciembre1728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/2191/1424Copyright (c) 2022 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/21912023-07-06T05:49:42Z
dc.title.none.fl_str_mv Neutralizing antibodies, new laboratory tests against SARS-CoV-2
Anticuerpos neutralizantes, nuevas pruebas de laboratorio contra el SARS-CoV-2
title Neutralizing antibodies, new laboratory tests against SARS-CoV-2
spellingShingle Neutralizing antibodies, new laboratory tests against SARS-CoV-2
Figueroa Montes, Luis Edgardo
Afinidad de Anticuerpos
Pruebas Serológicas
Infecciones por Coronavirus
Inmunogenicidad Vacunal
COVID-19
Antibody Affinity
Serologic Tests
Coronavirus Infections
Immunogenicity Vaccine
COVID-19
title_short Neutralizing antibodies, new laboratory tests against SARS-CoV-2
title_full Neutralizing antibodies, new laboratory tests against SARS-CoV-2
title_fullStr Neutralizing antibodies, new laboratory tests against SARS-CoV-2
title_full_unstemmed Neutralizing antibodies, new laboratory tests against SARS-CoV-2
title_sort Neutralizing antibodies, new laboratory tests against SARS-CoV-2
dc.creator.none.fl_str_mv Figueroa Montes, Luis Edgardo
Figueroa Montes, Luis Edgardo
author Figueroa Montes, Luis Edgardo
author_facet Figueroa Montes, Luis Edgardo
author_role author
dc.subject.none.fl_str_mv Afinidad de Anticuerpos
Pruebas Serológicas
Infecciones por Coronavirus
Inmunogenicidad Vacunal
COVID-19
Antibody Affinity
Serologic Tests
Coronavirus Infections
Immunogenicity Vaccine
COVID-19
topic Afinidad de Anticuerpos
Pruebas Serológicas
Infecciones por Coronavirus
Inmunogenicidad Vacunal
COVID-19
Antibody Affinity
Serologic Tests
Coronavirus Infections
Immunogenicity Vaccine
COVID-19
description Introduction: in this review we will know the details of this new laboratory test, used to quantify neutralizing antibodies against SARS-CoV-2. This diagnostic test begins to have a greater role, due to the process of infection and vaccination in the world, to understand the mysteries of the correlate of immune protection. Content: neutralizing antibodies have the ability to block the ability of the virus to bind to the ACE2 receptor in human cells and these antibodies allow to eliminate the effect of invading microorganisms. Their activity is generated by proteins on the surface of viruses, which they bind to "block" infection. Neutralizing antibodies are defined in vitro by their ability to block the entry, fusion or exit of the coronavirus, that is, they are functional antibodies. Summary: Currently there are different laboratory tests (high-throughput immunoassay tests), which have the ability to detect immunoglobulin G anti-protein S antibodies to SARS-CoV-2 and which correlate with the gold standard laboratory tests for the determination of these antibodies. It is crucial that these high-throughput immunoassay tests are manufacturing validated against gold standard methods to determine the presence of neutralizing antibodies. Perspective: this review aims to expand the knowledge of this new test, which in the future will allow defining the immunological correlate values ​​generated by vaccines or by a previous infection.
publishDate 2022
dc.date.none.fl_str_mv 2022-02-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/2191
10.35663/amp.2021.384.2191
url https://amp.cmp.org.pe/index.php/AMP/article/view/2191
identifier_str_mv 10.35663/amp.2021.384.2191
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/2191/1424
dc.rights.none.fl_str_mv Copyright (c) 2022 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol. 38 No. 4 (2021): October - December
ACTA MEDICA PERUANA; Vol. 38 Núm. 4 (2021): Octubre - Diciembre
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1843344787776733184
score 12.659675
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).